E Renaud

ORCID

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Venues

Oncogene

This page only lists publications with an associated author ORCID identifier.

Publications

Diana Bello Roufai, A Gonçalves, T De La Motte Rouge, S Akla, C Blonz, J Grenier, J Gligorov, M Saghatchian, C Bailleux, H Simon, I Desmoulins, Z Tharin, E Renaud, M Bertho, M-A Benderra, Suzette Delaloge, L Robert, P Cottu, J Y Pierga, D Loirat, A Bertucci, B Renouf, Francois-Clement Bidard, F Lerebours
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene (2023)
Diana Bello Roufai, A Gonçalves, T De La Motte Rouge, S Akla, C Blonz, J Grenier, J Gligorov, M Saghatchian, C Bailleux, H Simon, I Desmoulins, Z Tharin, E Renaud, M Bertho, M-A Benderra, Suzette Delaloge, L Robert, P Cottu, J Y Pierga, D Loirat, A Bertucci, B Renouf, Francois-Clement Bidard, F Lerebours
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene (2023)
Diana Bello Roufai, A Gonçalves, T De La Motte Rouge, S Akla, C Blonz, J Grenier, J Gligorov, M Saghatchian, C Bailleux, H Simon, I Desmoulins, Z Tharin, E Renaud, M Bertho, M-A Benderra, Suzette Delaloge, L Robert, P Cottu, J Y Pierga, D Loirat, A Bertucci, B Renouf, Francois-Clement Bidard, F Lerebours
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene (2023)
Diana Bello Roufai, A Gonçalves, T De La Motte Rouge, S Akla, C Blonz, J Grenier, J Gligorov, M Saghatchian, C Bailleux, H Simon, I Desmoulins, Z Tharin, E Renaud, M Bertho, M-A Benderra, Suzette Delaloge, L Robert, P Cottu, J Y Pierga, D Loirat, A Bertucci, B Renouf, Francois-Clement Bidard, F Lerebours
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene (2023)

E Renaud.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

E Renaud